Differences between osteoradionecrosis and medication-related osteonecrosis of the jaw

被引：21
作者：
Akashi M. [1 ]
Wanifuchi S. [1 ]
Iwata E. [1 ]
Takeda D. [1 ]
Kusumoto J. [1 ]
Furudoi S. [1 ]
Komori T. [1 ]
机构：
[1] Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, Kusunoki-cho 7-5-2, Chuo-ku, Kobe
来源：
Oral and Maxillofacial Surgery | 2018年 / 22卷 / 1期
关键词：
Computed tomography; Medication-related osteonecrosis of the jaw; Osteoradionecrosis of the jaw; Surgery;
D O I：
10.1007/s10006-017-0667-5
中图分类号：
学科分类号：
摘要：
Purpose: The appearance of osteoradionecrosis (ORN) and medication-related osteonecrosis of the jaw (MRONJ) is similar, but clinically important differences between ORN and MRONJ exist. The aim of this study was to compare the clinical data between ORN and MRONJ and to reveal the critical differences between these diseases. Methods: We retrospectively reviewed the epidemiological data, clinical findings, and treatment in 27 ORN and 61 MRONJ patients. Radiographic signs before the initiation of treatment were also assessed. Results: The median age (P = 0.0474) and the ratio of female to male patients (P < 0.0001) were significantly higher in MRONJ patients. There were significantly more MRONJ patients who reported a history of pain when compared with ORN patients (P = 0.0263). As an aetiological factor, tooth extraction was significantly more relevant to MRONJ than ORN (P = 0.0352). When assessing the radiographic signs on computed tomographic images, periosteal reaction was found only in MRONJ patients (P = 0.0158). Minimal debridement was performed significantly more frequently for MRONJ (P = 0.0093), and by contrast, surgical resection was performed more frequently for ORN (P = 0.0002). Conclusions: Understanding the clinical and underlying pathological differences between ORN and MRONJ probably contributes to the selection of appropriate treatment for each patient. © 2017, Springer-Verlag GmbH Germany, part of Springer Nature.
引用
收藏
页码：59 / 63
页数：4
相关论文
共 17 条
  • [1] Khan A.A., Morrison A., Hanley D.A., Felsenberg D., McCauley L.K., O'Ryan F., Reid I.R., Ruggiero S.L., Taguchi A., Tetradis S., Watts N.B., Brandi M.L., Peters E., Guise T., Eastell R., Cheung A.M., Morin S.N., Masri B., Cooper C., Morgan S.L., Obermayer-Pietsch B., Langdahl B.L., al Dabagh R., Davison K.S., Kendler D.L., Sandor G.K., Josse R.G., Bhandari M., el Rabbany M., Pierroz D.D., Sulimani R., Saunders D.P., Brown J.P., Compston J., Diagnosis and management of osteonecrosis of the jaw: a
  • [2] Owosho A.A., Tsai C.J., Lee R.S., Freymiller H., Kadempour A., Varthis S., Sax A.Z., Rosen E.B., Yom S.H.K., Randazzo J., Drill E., Riedel E., Patel S., Lee N.Y., Huryn J.M., Estilo C.L., The prevalence and risk factors associated with osteoradionecrosis of the jaw in oral and oropharyngeal cancer patients treated with intensity-modulated radiation therapy (IMRT): the Memorial Sloan Kettering Cancer Center experience, Oral Oncol, 64, pp. 44-51, (2017)
  • [3] Chen J.A., Wang C.C., Wong Y.K., Wang C.P., Jiang R.S., Lin J.C., Chen C.C., Liu S.A., Osteoradionecrosis of mandible bone in patients with oral cancer—associated factors and treatment outcomes, Head Neck, 38, 5, pp. 762-768, (2016)
  • [4] Grisar K., Schol M., Schoenaers J., Dormaar T., Coropciuc R., Vander Poorten V., Politis C., Osteoradionecrosis and medication-related osteonecrosis of the jaw: similarities and differences, Int J Oral Maxillofac Surg, 45, 12, pp. 1592-1599, (2016)
  • [5] Obinata K., Shirai S., Ito H., Nakamura M., Carrozzo M., Macleod I., Carr A., Yamazaki Y., Tei K., Image findings of bisphosphonate related osteonecrosis of jaws comparing with osteoradionecrosis, Dentomaxillofac Radiol, 46, 5, (2017)
  • [6] Bagan J.V., Jimenez Y., Hernandez S., Murillo J., Diaz J.M., Poveda R., Carbonell E., Sanchis J.M., Gavalda C., Scully C., Osteonecrosis of the jaws by intravenous bisphosphonates and osteoradionecrosis: a comparative study, Med Oral Patol Oral Cir Bucal, 14, 12, pp. e616-e619, (2009)
  • [7] Hansen T., Kunkel M., Weber A., James Kirkpatrick C., Osteonecrosis of the jaws in patients treated with bisphosphonates—histomorphologic analysis in comparison with infected osteoradionecrosis, J Oral Pathol Med, 35, 3, pp. 155-160, (2006)
  • [8] Yoneda T., Hagino H., Sugimoto T., Ohta H., Takahashi S., Et al., Antiresorptive agent-related osteonecrosis of the jaw: position paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw, J Bone Miner Metab, 35, pp. 6-19, (2017)
  • [9] Ruggiero S.L., Dodson T.B., Fantasia J., Goodday R., Aghaloo T., Mehrotra B., O'Ryan F., American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update, J Oral Maxillofac Surg, 72, 10, pp. 1938-1956, (2014)
  • [10] Jacobson A.S., Buchbinder D., Hu K., Urken M.L., Paradigm shifts in the management of osteoradionecrosis of the mandible, Oral Oncol, 46, 11, pp. 795-801, (2010)
12